Skip to main content

Table 1 The basic features of the included literature

From: Comparison of platinum monotherapy with concurrent chemoradiation therapy versus platinum-based dual drug therapy with concurrent chemoradiation therapy for locally advanced cervical cancer: a systematic review and meta-analysis

Author

Year

Type of study

FIGO Stage

Median age (exp/ctr)

Patients (exp/ctr)

Treatment

HR (95% CI)

RT doses

CT regimens

OS

PFS

Alfonso [23]

2005

Prospective

IB2–IIB

41/49

43/40

EBRT 50 Gy + BT 30–35 Gy if high risk factors

Cisplatin + GEM/ cisplatin

0.18 (0.01–3.80)

0.17 (0.02–1.49)

Veerasarn [15]

2007

Prospective

IIB–IVA

49.6/49.7

234/235

EBRT 40–50 Gy/20–25 F + ICRT

Tegafur-uracil + carboplatin/carboplatin

0.90 (0.52–1.56)

 

Peter [18]

2007

Prospective

IIB–III

NR

176/173

EBRT 40.8–51 Gy + BT 30–40 Gy

Cisplatin + 5-FU + HU/ cisplatin

0.90 (0.59–1.38)

0.99 (0.65–1.51)

Kim [21]

2008

Prospective

IIB–IVA

60/57

79/79

EBRT 41.4–50.4 Gy/23–28 F + ICRT 30–35 Gy/6–7 F

5-FU + cisplatin/ cisplatin

0.98 (0.47–2.04)

1.28 (0.68–2.41)

Torres [16]

2008

Prospective

III–IV

NR

191/111

EBRT 45 Gy (most pts) + LDR BT (most pts)

Cisplatin + 5-FU / cisplatin

0.42 (0.25–0.69)

 

Alfonso [22]

2011

Prospective

IIB–IVA

45/46

259/256

EBRT 50.4 Gy/28 F + ICRT 30 Gy/6 F

GEM + cisplatin/ cisplatin

0.68 (0.49–0.95)

0.68 (0.49–0.95)

Nedovic [12]

2012

Retrospective

IIB–IVA

51/54

64/70

EBRT 50.4–54 Gy/20–30 F + ICRT 30–34 Gy/5 F

5-FU + cisplatin/ cisplatin

0.66 (0.34–1.28)

0.68 (0.37–0.99)

Tang [13]

2012

Retrospective

IIB–IVA

53/57

440/440

EBRT 48–50 Gy/24–25F + ICRT 24 Gy/4 F

PAC + cisplatin/ cisplatin

0.76 (0.56–1.04)

0.62 (0.48–0.80)

Donnelly [10]

2013

Retrospective

IB1–IVA

NR

42/95

EBRT 51.42 + LDR-BT

Cisplatin + 5-FU/ cisplatin

0.85 (0.38–1.92)

0.84 (0.39–1.83)

Lee [11]

2013

Retrospective

IB–IIA

45.5/44.5

21/34

EBRT 50.4 Gy (BT not done)

Cisplatin + CTX or cisplatin + 5-FU or carboplatin + 5-FU or carboplatin + PAC/ cisplatin

0.78 (0.17–3.51)

0.26 (0.07–0.95)

Pu [19]

2013

Prospective

IB–IIA

47/45

145/140

EBRT 46–54 Gy + BT 24 Gy

Cisplatin + DOC/ cisplatin

0.65 (0.39–1.09)

0.64 (0.40–1.03)

Wang [8]

2015

Prospective

III–IVA

55/56

37/37

EBRT 45 Gy/25 F + ICRT 25.8 Gy/6 F

GEM + cisplatin/ cisplatin

0.93 (0.35–2.47)

0.86 (0.39–1.91)

Li [20]

2015

Prospective

IIB–IVA

51.7/49.8

36/36

EBRT 50 Gy/25 F + ICRT 10 Gy/2 F

S-1 + cisplatin/ cisplatin

0.86 (0.32–2.31)

0.89 (0.28–2.71)

Thakur [17]

2016

Prospective

IIA–IIIB

NR

39/42

EBRT 50 Gy/25 F + ICRT 10 Gy/3 F

PAC + cisplatin/ cisplatin

0.54 (0.18–1.61)

0.47 (0.20–1.09)

Zhao [14]

2016

Retrospective

IA2–MIIB

50/52

75/71

EBRT 46–50 Gy/23–25 F + BT 30 Gy/ 5F

PAC + cisplatin consolidation/PAC + cisplatin

0.70 (0.31–1.60)

0.80 (0.38–1.67)

Samantha [24]

2019

Prospective

IIB–IVA

48/45

55/52

EBRT 45 Gy/25–28 F + BT 28–30 Gy/4–5 F

Cisplatin + GEM/ cisplatin

2.79 (1.29–6.01)

1.84 (1.04–3.26)

Siriwan [4]

2019

Prospective

IIB–IVA

49/50

130/129

EBRT 54 Gy + ICRT 28 Gy

Cisplatin + carboplatin + PAC/ cisplatin

1.42 (0.81–2.49)

1.26 (0.82–1.96)

  1. NR not reported, exp experimental group, ctr control group, CT chemical therapy, RT radiotherapy, EBRT external beam radiotherapy, ICRT intracavitary radiotherapy, BT brachytherapy, LDR low dose rate, HU hydroxyurea, 5-FU 5-Fluorouracil, GEM Gemcitabine, DOC docetaxel, PAC paclitaxel, CTX cyclophosphamide